Stocktoria
Tvardi Therapeutics, Inc. TVRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Tvardi Therapeutics, Inc. statistics & valuation
Market cap$14.1M
P / B0.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -393.8% | -579.4% | -209.1% | -386.8% |
| Net margin | — | -411.9% | -565.2% | -204.2% | -384.1% |
| FCF margin | — | -271.1% | -450.5% | -188.2% | -261.1% |
| Return on assets | -56.8% | -83.5% | -94.2% | -46.9% | -35.8% |
| Return on equity | -87.0% | 32.3% | 191.0% | -53.8% | -38.9% |
| Current ratio | 2.86 | 3.06 | 4.54 | 7.20 | 9.84 |
| Revenue growth | — | -66.0% | -49.9% | 81.8% | -83.0% |
Source: SEC EDGAR filings · CIK 0001346830 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.